Compare XXII & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XXII | CMND |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 5.3M |
| IPO Year | N/A | N/A |
| Metric | XXII | CMND |
|---|---|---|
| Price | $1.04 | $0.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 190.3K | ★ 37.7M |
| Earning Date | 11-04-2025 | 01-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $20,346,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $136.46 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.98 | N/A |
| 52 Week Low | $0.78 | $0.10 |
| 52 Week High | $294.98 | $2.18 |
| Indicator | XXII | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 47.06 | 16.70 |
| Support Level | $0.98 | $0.10 |
| Resistance Level | $1.09 | $0.13 |
| Average True Range (ATR) | 0.09 | 0.04 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 83.36 | 7.87 |
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.